US-based compact proton therapy technology company ProTom International on Friday unveiled its new Radiance 330-C Proton Therapy System, a compact and modular proton therapy solution.
The fixed-beam system allows healthcare providers to add single or multiple treatment rooms within existing Linac vaults in radiation oncology departments, reducing overall costs.
Integrated with Leo Cancer Care's upright patient positioning and imaging system, the Radiance 330-C offers gantry-less proton therapy without compromising treatment quality.
It features Fidelity pencil beam scanning technology, enabling precise dose delivery and real-time adaptive therapy.
The system's stationary beam delivery enhances reliability and reduces maintenance, while its compact synchrotron accelerator supports a treatment energy range of 70 MeV to 250 MeV.
ProTom added that the system is not yet available for clinical use.
Medivir partners with Eisai to evaluate fostrox in liver cancer
OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis
Cytoki Pharma doses first patient with CK-0045 in Phase two proof-of-concept trial
Formosa Pharmaceuticals signs licensing agreement with DÁVI Farmaceutica
Alchemy partners with PatchRx to improve HIV medication adherence
Bexion Pharmaceuticals reports release of first-in-human data from Phase 1 study of BXQ-350
HUTCHMED receives milestone payment from Takeda for FRUZAQLA sales
Hemogenyx Pharmaceuticals schedules Phase i clinical trial for HEMO-CAR-T
SciBase and Kilabs partner to advance skin cancer diagnostics in Italy
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
UZ Leuven chooses Sectra for enhanced cancer diagnostics
Biond Biologics signs clinical trial collaboration and supply agreement with Merck KGaA
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI